Statistik Asas
| CIK | 1488613 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Foundation Medicine, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| September 18, 2018 |
10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num |
|
| September 18, 2018 |
EX-10.1 Exhibit 10.1 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 Execution Version AMENDED AND RESTATED SUPPLY, SERVICE, AND SUPPORT AGREEMENT This Amended and Restated Supply, Service, and Support Agreement (this “Agreement”) is effective as of the date of last signature found |
|
| August 10, 2018 |
FMI / Foundation Medicine, Inc. 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36086 FOUNDATION MEDICINE, INC. (Exact name of registrant as specified i |
|
| August 9, 2018 |
Exhibit 10.1 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 Execution Version AMENDED AND RESTATED SUPPLY, SERVICE, AND SUPPORT AGREEMENT This Amended and Restated Supply, Service, and Support Agreement (this “Agreement”) is effective as of the date of last signature found below ( |
|
| August 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36086 FOUNDATION MEDICINE, INC. |
|
| August 9, 2018 |
Exhibit 10.2 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 Execution Version CHINA TERRITORY AGREEMENT This China Territory Agreement (“Agreement”) is entered into by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070, Basel, |
|
| August 3, 2018 |
FMI / Foundation Medicine, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on August 3, 2018 Registration No. |
|
| August 3, 2018 |
FMI / Foundation Medicine, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on August 3, 2018 Registration No. |
|
| August 3, 2018 |
FMI / Foundation Medicine, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on August 3, 2018 Registration No. |
|
| August 3, 2018 |
FMI / Foundation Medicine, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on August 3, 2018 Registration No. |
|
| August 3, 2018 |
FMI / Foundation Medicine, Inc. FORM S-8 POS As filed with the Securities and Exchange Commission on August 3, 2018 Registration No. |
|
| July 31, 2018 |
Bylaws of the Company (filed herewith). EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF FOUNDATION MEDICINE, INC. * * * * * ARTICLE 1 OFFICES Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaware as the Boar |
|
| July 31, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 31, 2018 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commis |
|
| July 31, 2018 |
Amended and Restated Certificate of Incorporation of the Company (filed herewith). EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FOUNDATION MEDICINE, INC. FIRST: The name of the corporation is Foundation Medicine, Inc. (the “Corporation”). SECOND: The address of its registered office in the State of Delaware is 251 Little Falls Drive, City of Wilmington, County of New Castle, Delaware 19808. The name of its registered agent at such address is Corporatio |
|
| July 31, 2018 |
FMI / Foundation Medicine, Inc. SC 14D9/A SC 14D9/A 1 d553552dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Foundation Medicine, Inc. (Name of Subject Company) Foundation Medicine, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE |
|
| July 31, 2018 |
Exhibit (a)(5)(vii) Media Release Basel, 31 July 2018 Roche Purchases Shares in Tender Offer for FMI Roche (SIX: RO, ROG; OTCQX: RHHBY) and Foundation Medicine, Inc. |
|
| July 31, 2018 |
FMI / Foundation Medicine, Inc. FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) FOUNDATION MEDICINE, INC. (Name of Subject Company) 062018 Merger Subsidiary, Inc. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons – Offeror) Co |
|
| July 31, 2018 |
FMI / Foundation Medicine, Inc. / ROCHE HOLDING LTD - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 4) Under the Securities Exchange Act of 1934 Foundation Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 350456100 (CUSIP Number) Beat Kraehenmann Roche Holding Ltd Grenzacherstrasse 124 CH-4070 Basel, Switzerland Telephone: +41-61-688-1111 ( |
|
| July 31, 2018 |
FMI / Foundation Medicine, Inc. / Foundation Medicine, Inc. - SC 13E3/A SC 13E3/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) (Amendment No. 2) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Foundation Medicine, Inc. (Name of the Issuer) Foundation Medicine, Inc. (Name of Person(s) Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 350465100 |
|
| July 18, 2018 |
EX-10.1 Exhibit 10.1 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 Execution Version Amended and Restated Ex-US Commercialization Agreement This Amended and Restated Ex-US Commercialization Agreement is entered into as of February 28, 2018 (the “Restatement Date”) by and between |
|
| July 18, 2018 |
FMI / Foundation Medicine, Inc. FORM 10-Q/A (Quarterly Report) Form 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fi |
|
| July 17, 2018 |
FMI / Foundation Medicine, Inc. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Foundation Medicine, Inc. (Name of Subject Company) Foundation Medicine, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Clas |
|
| July 17, 2018 |
FMI / Foundation Medicine, Inc. FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) FOUNDATION MEDICINE, INC. (Name of Subject Company) 062018 Merger Subsidiary, Inc. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons – Offeror) Co |
|
| July 17, 2018 |
FMI / Foundation Medicine, Inc. / Foundation Medicine, Inc. - SC 13E3/A SC 13E3/A 1 d522533dsc13e3a.htm SC 13E3/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) (Amendment No. 1) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Foundation Medicine, Inc. (Name of the Issuer) Foundation Medicine, Inc. (Name of Person(s) Filing Statement) Common Stock, $0.0001 par value per share (Title o |
|
| July 17, 2018 |
FMI / Foundation Medicine, Inc. CORRESP CORRESP July 17, 2018 VIA EDGAR Daniel F. Duchovny Special Counsel Office of Mergers and Acquisitions Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Foundation Medicine, Inc. Schedule 13E-3 filed by Foundation Medicine, Inc. Filed July 2, 2018 File No. 005-87922 Schedule 14D-9 filed July 2, 2018 SEC File No. 005-87922 De |
|
| July 2, 2018 |
FMI / Foundation Medicine, Inc. FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) FOUNDATION MEDICINE, INC. (Name of Subject Company) 062018 Merger Subsidiary, Inc. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons – Offeror) Co |
|
| July 2, 2018 |
EXHIBIT (a)(5)(vi) Media Release Roche commences tender offer for all shares of Foundation Medicine, Inc. |
|
| July 2, 2018 |
FMI / Foundation Medicine, Inc. SC 14D9 SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 2, 2018 |
EX-(a)(1)(i) Table of Contents Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Foundation Medicine, Inc. |
|
| July 2, 2018 |
EX-(a)(1)(v) Exhibit (a)(1)(v) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Foundation Medicine, Inc. |
|
| July 2, 2018 |
EX-(a)(1)(ii) Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of Foundation Medicine, Inc. |
|
| July 2, 2018 |
EX-(a)(1)(vi) Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| July 2, 2018 |
EX-(a)(1)(iii) Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of Foundation Medicine, Inc. |
|
| July 2, 2018 |
FMI / Foundation Medicine, Inc. FORM SC TO-T SC TO-T 1 dp92982sctot.htm FORM SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 FOUNDATION MEDICINE, INC. (Name of Subject Company) 062018 Merger Subsidiary, Inc. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing |
|
| July 2, 2018 |
EX-(a)(1)(iv) Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Foundation Medicine, Inc. |
|
| July 2, 2018 |
FMI / Foundation Medicine, Inc. / Foundation Medicine, Inc. - SC 13E3 SC 13E3 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Foundation Medicine, Inc. (Name of the Issuer) Foundation Medicine, Inc. (Name of Person(s) Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 350465100 (CUSIP Number of Cl |
|
| July 2, 2018 |
EX-99.(C).2 Exhibit (c)(2) CONFIDENTIAL DRAFT INVESTMENT BANKING DIVISION Project Cake Financial Analysis Overview Goldman Sachs & Co. LLC June 18, 2018 Goldman Sachs does not provide accounting, tax, or legal advice. Notwithstanding anything in this document to the contrary, and except as required to enable compliance with applicable securities law, you (and each of your employees, representative |
|
| June 21, 2018 |
Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 21, 2018 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commis |
|
| June 19, 2018 |
FMI / Foundation Medicine, Inc. SC14D9C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Foundation Medicine, Inc. (Name of Subject Company) Foundation Medicine, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per Share (Title of Class of Securities) 350456100 (CUSIP Number |
|
| June 19, 2018 |
FMI / Foundation Medicine, Inc. SC14D9C SC14D9C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Foundation Medicine, Inc. (Name of Subject Company) Foundation Medicine, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per Share (Title of Class of Securities) 350456100 (CUSIP |
|
| June 19, 2018 |
FMI / Foundation Medicine, Inc. SC14D9C SC14D9C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Foundation Medicine, Inc. (Name of Subject Company) Foundation Medicine, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.0001 per Share (Title of Class of Securities) 350456100 (CUSIP |
|
| June 19, 2018 |
EX-99.1 Exhibit 99.1 Media Release Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology • Together, the companies will leverage expertise in genomics and molecular information to enhance the development of personalised medicines and care for patients with cancer • Merger focuses on driving ubiquity of Founda |
|
| June 19, 2018 |
EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER dated as of June 18, 2018 among FOUNDATION MEDICINE, INC., ROCHE HOLDINGS, INC. and 062018 MERGER SUBSIDIARY, INC. TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 2 Section 1.02. Other Definitional and Interpretative Provisions 10 ARTICLE 2 THE OFFER Section 2.01. The Offer 10 Section 2.02. Company Action 12 A |
|
| June 19, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 18, 2018 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commis |
|
| June 19, 2018 |
Exhibit 99.1 AGREEMENT AND PLAN OF MERGER dated as of June 18, 2018 among FOUNDATION MEDICINE, INC., ROCHE HOLDINGS, INC. and 062018 Merger Subsidiary, Inc. TABLE OF CONTENTS Page Article 1 Definitions Section 1.01. Definitions 1 Section 1.02. Other Definitional and Interpretative Provisions 10 Article 2 The Offer Section 2.01. The Offer 10 Section 2.02. Company Action 12 Article 3 The Merger Sect |
|
| June 19, 2018 |
FMI / Foundation Medicine, Inc. / ROCHE HOLDING LTD - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 3) Under the Securities Exchange Act of 1934 Foundation Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 350456100 (CUSIP Number) Beat Kraehenmann Roche Holding Ltd Grenzacherstrasse 124 CH-4070 Basel, Switzerland Telephone: +41-61-688-1111 ( |
|
| June 7, 2018 |
Entry into a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 6, 2018 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commiss |
|
| May 2, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 2, 2018 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commissi |
|
| May 2, 2018 |
Foundation Medicine Announces 2018 First Quarter Results and Recent Highlights EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Foundation Medicine Announces 2018 First Quarter Results and Recent Highlights CAMBRIDGE, Mass. –May 2, 2018—Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the first quarter ended March 31, 2018. Highlights for the quarter included: • Posted revenue of $52.8 million, 101% year-over-year growth; • Reported 21,861 clin |
|
| May 2, 2018 |
Exhibit 10.2 December 5, 2016 Michael Doherty Re: Employment with Foundation Medicine, Inc. Dear Michael: On behalf of Foundation Medicine, Inc. (“Foundation Medicine” or “the Company”), I am very pleased to offer you the position of Head of Product Development. The terms of your position with the Company are as set forth below in this letter agreement (“Agreement”): 1. Position and Start Date. Yo |
|
| May 2, 2018 |
Exhibit 10.4 September 12, 2016 Melanie Nallicheri Re:Employment with Foundation Medicine, Inc. Dear Melanie: On behalf of Foundation Medicine, Inc. (“Foundation Medicine” or “the Company”), I am very pleased to offer you the position of Chief Business Officer and Head, Biopharma. The terms of your position with the Company are as set forth below in this letter agreement (“Agreement”): 1. Position |
|
| May 2, 2018 |
FMI / Foundation Medicine, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36086 FOUNDATION MEDICINE, INC. |
|
| May 2, 2018 |
Exhibit 10.1 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 Execution Version Amended and Restated Ex-US Commercialization Agreement This Amended and Restated Ex-US Commercialization Agreement is entered into as of February 28, 2018 (the “Restatement Date”) by and between F. Hoffm |
|
| May 2, 2018 |
Exhibit 10.3 150 Second Street, 1st Floor Cambridge Massachusetts 02141 TEL 617.418.2200 FAX 617.418.2201 May 1, 2018 Konstantin Fiedler Re: Employment with FMI Germany GmbH and Foundation Medicine, Inc. Dear Konstantin: As you are aware, you are currently employed as the Managing Director of FMI Germany GmbH, a German corporation (“FMI Germany”) that is a wholly owned subsidiary of Foundation Med |
|
| April 27, 2018 |
FMI / Foundation Medicine, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filedby the Registrant x Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 27, 2018 |
FMI / Foundation Medicine, Inc. DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitte |
|
| March 19, 2018 |
EX-99.1 Exhibit 99.1 NEWS RELEASE Foundation Medicine Announces Final National Coverage Determination (NCD) from the Centers for Medicare & Medicaid Services (CMS), Including Coverage for FoundationOne CDx™ Across All Solid Tumors — Final NCD Significantly Expands Patient Access Beyond the Preliminary NCD — CAMBRIDGE, Mass. – March 18, 2018 - Foundation Medicine, Inc. (NASDAQ:FMI) today announced |
|
| March 19, 2018 |
FMI / Foundation Medicine, Inc. 8-K (Current Report) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 16, 2018 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commi |
|
| March 7, 2018 |
FMI / Foundation Medicine, Inc. S-8 S-8 As filed with the Securities and Exchange Commission on March 7, 2018 Registration No. |
|
| March 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 7, 2018 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commission |
|
| March 7, 2018 |
Exhibit 99.1 Foundation Medicine Announces 2017 Fourth Quarter and Year-End Results, Recent Highlights and 2018 Outlook CAMBRIDGE, Mass.-(BUSINESS WIRE)-March 7, 2018-Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the fourth quarter and year ended December 31, 2017. Highlights for the quarter and year included: Fourth quarter revenue of $48.9 million, 70% yea |
|
| March 7, 2018 |
Exhibit 21.1 SUBSIDIARIES OF REGISTRANT Name State or Country of Incorporation or Organization Foundation Medicine Securities Corporation Massachusetts FMI Germany, GmbH Germany |
|
| March 7, 2018 |
FMI / Foundation Medicine, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36086 FOUNDATION MEDI |
|
| March 7, 2018 |
EX-10.30 3 fmi-ex1030431.htm EX-10.30 Exhibit 10.30 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 SECOND AMENDMENT TO EX-US COMMERCIALIZATION AGREEMENT This Second Amendment to Ex-US Commercialization Agreement (“Second Amendment”), effective as of October 10, 2017 (“Second Amend |
|
| March 7, 2018 |
Exhibit 10.31 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 THIRD AMENDMENT TO EX-US COMMERCIALIZATION AGREEMENT This Third Amendment to Ex-US Commercialization Agreement (“Third Amendment”), is entered into as of December 8, 2017 (“Third Amendment Execution Date”) and shall be e |
|
| March 7, 2018 |
EX-10.27 2 fmi-ex1027432.htm EX-10.27 Exhibit 10.27 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 SIXTH AMENDMENT TO COLLABORATION AGREEMENT This Sixth Amendment (“Sixth Amendment”) to the Collaboration Agreement (the “Agreement”) by and between F. Hoffmann-La Roche Ltd, with an |
|
| March 5, 2018 |
Entry into a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 28, 2018 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Co |
|
| January 8, 2018 |
Exhibit 99.1 Foundation Medicine Reports Preliminary 2017 Results Reports Total Revenue of Approximately $152.9 Million, a 31% Year Over Year Increase; Reports 67,375 Clinical Tests in 2017, a 54% Year Over Year Increase Increases Biopharma Revenue Approximately 27% Year-Over-Year with New and Expanded Collaborations Achieves Significant Milestone with FDA Approval and Preliminary National Coverag |
|
| January 8, 2018 |
EX-99.2 3 a51739267ex992.htm EXHIBIT 99.2 Exhibit 99.2 Personalized Cancer Care. Delivered. JP Morgan Healthcare Conference 2018 January 8, 2018 CONFIDENTIAL Forward Looking Statement January 8, 2018 This presentation contains forward-looking statements about our business. These statements may be identified by words such as “may,” “will,” “should,” “could,” “expect,” “intend,” “plan,” “anticipate, |
|
| January 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2018 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commissi |
|
| December 22, 2017 |
EX-4.2 3 d506863dex42.htm EX-4.2 Exhibit 4.2 FOUNDATION MEDICINE, INC. TO Trustee Indenture Dated as of , 20 Subordinated Debt Securities TABLE OF CONTENTS Page ARTICLE ONE - DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 SECTION 101. Definitions 1 SECTION 102. Compliance Certificates and Opinions 8 SECTION 103. Form of Documents Delivered to Trustee 9 SECTION 104. Acts of Holders 9 SEC |
|
| December 22, 2017 |
Computation of Ratio of Earnings to Fixed Charges EX-12.1 Exhibit 12.1 Computation of Ratio of Earnings to Fixed Charges Year ended December 31, Nine months ended September 30, 2016 2015 2014 2017 (in thousands) Net loss $ (113,192 ) $ (89,631 ) $ (52,222 ) $ (123,355 ) Fixed charges: Interest expense on indebtedness 143 — — 286 Noncash interest expense and other — — 3 284 Total fixed charges 143 — 3 570 Net loss plus fixed charges $ (113,049 ) $ |
|
| December 22, 2017 |
Form of indenture for senior debt securities and the related form of senior debt security EX-4.1 2 d506863dex41.htm EX-4.1 Exhibit 4.1 FOUNDATION MEDICINE, INC. TO Trustee Indenture Dated as of , 20 Senior Debt Securities TABLE OF CONTENTS Page ARTICLE ONE - DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 SECTION 101. Definitions 2 SECTION 102. Compliance Certificates and Opinions 8 SECTION 103. Form of Documents Delivered to Trustee 8 SECTION 104. Acts of Holders 9 SECTION 1 |
|
| December 22, 2017 |
As filed with the Securities and Exchange Commission on December 22, 2017. S-3ASR Table of Contents As filed with the Securities and Exchange Commission on December 22, 2017. |
|
| December 19, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2017 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Co |
|
| December 1, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 30, 2017 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commis |
|
| December 1, 2017 |
Exhibit 99.1 FDA Approves Foundation Medicine?s FoundationOne CDx?, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics -Landmark approval advances personalized cancer care as an estimated 1 in 3 patients across five common advanced cancers are expected to match with an FDA-approved therapy- -The Centers for Medicare and Medicai |
|
| November 1, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 1, 2017 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commiss |
|
| November 1, 2017 |
Foundation Medicine Announces 2017 Third Quarter Results and Recent Highlights Exhibit 99.1 Foundation Medicine Announces 2017 Third Quarter Results and Recent Highlights CAMBRIDGE, Mass.-(BUSINESS WIRE)-November 1, 2017-Foundation Medicine, Inc. (NASDAQ: FMI) today reported financial and operating results for its third quarter ended September 30, 2017. Results and business highlights for the quarter included: Achieved third quarter revenue of $42.7 million, 45% year-over-ye |
|
| November 1, 2017 |
FMI / Foundation Medicine, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36086 FOUNDATION MEDICINE, INC. |
|
| October 10, 2017 |
Foundation Medicine Appoints Tom Civik as Chief Commercial Officer EX-99.1 Exhibit 99.1 NEWS RELEASE Foundation Medicine Appoints Tom Civik as Chief Commercial Officer CAMBRIDGE, Mass. ? October 10, 2017?Foundation Medicine, Inc. (NASDAQ:FMI) today announced the appointment of Tom Civik to the role of chief commercial officer. Mr. Civik brings to Foundation Medicine more than two decades of commercial and operational experience with global biopharmaceutical organ |
|
| October 10, 2017 |
Foundation Medicine 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 10, 2017 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Com |
|
| October 10, 2017 |
Executive Employee Offer Letter by and between the Company and Tom Civik, dated October 10, 2017 EX-10.1 Exhibit 10.1 150 Second Street, 1st Floor October 6, 2017 Cambridge Massachusetts 02141 VIA ELECTRONIC MAIL TEL 617.418.2200 FAX 617.418.2201 Mr. Tom Civik 261 Oakdale Avenue Mill Valley, CA 94941 Re: Employment with Foundation Medicine, Inc. Dear Tom: On behalf of Foundation Medicine, Inc. (?Foundation Medicine? or ?the Company?), I am very pleased to offer you employment with the Company |
|
| September 13, 2017 |
EX-10.1 Exhibit 10.1 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 FIFTH AMENDMENT TO COLLABORATION AGREEMENT This Fifth Amendment (?Fifth Amendment?) to the Collaboration Agreement (the ?Agreement?) by and between F. Hoffmann-La Roche Ltd, with an office and place of business at |
|
| September 13, 2017 |
Foundation Medicine 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 8, 2017 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Co |
|
| August 1, 2017 |
EX-10.1 Exhibit 10.1 Foundation Medicine, Inc. 150 Second Street Cambridge, MA 02141 USA July 31, 2017 Amendment Letter Agreement (the ?Amendment Letter Agreement?) Ladies and Gentlemen, Reference is made to the Credit Facility Agreement, dated August 02, 2016 (the ?Credit Agreement?) and the Side Letter Agreement, dated August 02, 2016 (the ?Side Letter Agreement ?), each by and among Foundation |
|
| August 1, 2017 |
Foundation Medicine FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 31, 2017 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (C |
|
| August 1, 2017 |
Foundation Medicine Announces 2017 Second Quarter Results and Recent Highlights EX-99.1 Exhibit 99.1 NEWS RELEASE Foundation Medicine Announces 2017 Second Quarter Results and Recent Highlights CAMBRIDGE, Mass. ? August 1, 2017 - Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its second quarter ended June 30, 2017. Results and business highlights for the quarter included: ? Achieved second quarter revenue of $35.0 million, 24% year-o |
|
| August 1, 2017 |
Exhibit 10.1 AMENDMENT #2 TO SUPPLY, SERVICE, AND SUPPORT AGREEMENT Illumina, Inc., a Delaware corporation having a place of business at 5200 Illumina Way, San Diego, CA 92122 and Foundation Medicine Inc., having a place of business at 150 Second Street, Cambridge, MA 02141, entered into that certain Supply, Service, and Support Agreement dated July 25, 2013, as amended by Amendment #1 dated Octob |
|
| August 1, 2017 |
FMI / Foundation Medicine, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36086 FOUNDATION MEDICINE, INC. |
|
| June 27, 2017 |
CORRESP 1 filename1.htm June 27, 2017 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attention: Joel Parker, Senior Assistant Chief Accountant Office of Beverages, Apparel, and Mining Re: Foundation Medicine, Inc. Form 10-K for the fiscal year ended December 31, 2016 Filed March 3, 2017 File No. 001-36086 Dear Mr. Parker: W |
|
| June 21, 2017 |
Foundation Medicine 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 20, 2017 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commis |
|
| May 19, 2017 |
CORRESP 1 filename1.htm May 19, 2017 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attention: Joel Parker, Senior Assistant Chief Accountant Office of Beverages, Apparel, and Mining Re: Foundation Medicine, Inc. Form 10-K for the fiscal year ended December 31, 2016 Filed March 3, 2017 File No. 001-36086 Dear Mr. Parker: We |
|
| May 9, 2017 |
Foundation Medicine FORM 10-Q (Quarterly Report) fmi-10q20170331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 9, 2017 |
Foundation Medicine Announces 2017 First Quarter Results and Recent Highlights Exhibit 99.1 Foundation Medicine Announces 2017 First Quarter Results and Recent Highlights CAMBRIDGE, Mass.-(BUSINESS WIRE)-May 9, 2017-Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its first quarter ended March 31, 2017. Results and business highlights for the quarter included: Reported 13,933 clinical tests in the first quarter, 55% year-over-year gro |
|
| May 9, 2017 |
Foundation Medicine FOUNDATION MEDICINE, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2017 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commission F |
|
| May 4, 2017 |
EXHIBIT 3 POWER OF ATTORNEY The undersigned, Daniel J. Donoghue, hereby appoints Mark Buckley his true and lawful attorney-in-fact and agent, with full power to execute and file with the United States Securities and Exchange Commission and any stock exchange or similar authority, for and on his behalf in any and all capacities, any and all reports required to be filed pursuant to Section 13 of the |
|
| May 4, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Foundation Medicine, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Secur |
|
| May 4, 2017 |
EXHIBIT 2 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Amendment No. |
|
| May 4, 2017 |
TRANSACTIONS DURING PAST 60 DAYS EXHIBIT 1 TRANSACTIONS DURING PAST 60 DAYS The Reporting Persons engaged in the following transactions in shares of Common Stock of the Company during the past 60 days. |
|
| April 28, 2017 |
Foundation Medicine ADDITIONAL MATERIAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2017 |
Foundation Medicine DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 12, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 12, 2017 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) ( |
|
| March 30, 2017 |
AMENDMENT #1 TO SUPPLY, SERVICE, AND SUPPORT AGREEMENT EX-10.11 Exhibit 10.11 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 AMENDMENT #1 TO SUPPLY, SERVICE, AND SUPPORT AGREEMENT Illumina, Inc., a Delaware corporation having a place of business at 5200 Illumina Way, San Diego, CA 92122 (?Illumina?) and Foundation Medicine Inc., havin |
|
| March 30, 2017 |
Foundation Medicine FORM 10-K/A (Annual Report) Form 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file nu |
|
| March 3, 2017 |
EX-10.24 3 fmi-ex1024251.htm EX-10.24 Exhibit 10.24 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 FOURTH AMENDMENT TO COLLABORATION AGREEMENT This Fourth Amendment (“Fourth Amendment”) to the Collaboration Agreement (the “Agreement”) by and between F. Hoffmann-La Roche Ltd, with |
|
| March 3, 2017 |
EX-21.1 4 fmi-ex211249.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES OF REGISTRANT Name State or Country of Incorporation or Organization Foundation Medicine Securities Corporation Massachusetts FMI Germany, GmbH Germany |
|
| March 3, 2017 |
AMENDMENT #1 TO SUPPLY, SERVICE, AND SUPPORT AGREEMENT EX-10.11 2 fmi-ex1011250.htm EX-10.11 Exhibit 10.11 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 AMENDMENT #1 TO SUPPLY, SERVICE, AND SUPPORT AGREEMENT Illumina, Inc., a Delaware corporation having a place of business at 5200 Illumina Way, San Diego, CA 92122 (“Illumina”) and Fo |
|
| March 2, 2017 |
S-8 As filed with the Securities and Exchange Commission on March 2, 2017 Registration No. |
|
| March 2, 2017 |
Foundation Medicine 10-K (Annual Report) fmi-10k20161231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3 |
|
| March 2, 2017 |
Exhibit 99.1 Foundation Medicine Receives Medicare Payment in Non-Small Cell Lung Cancer under a Local Coverage Determination for FoundationOne?, the Company?s Comprehensive Genomic Profiling Assay CAMBRIDGE, Mass.-(BUSINESS WIRE)-March 2, 2017-Foundation Medicine, Inc. (NASDAQ:FMI) today announced that it has received payment from Palmetto GBA, the Company?s Medicare Administrative Contractor (MA |
|
| March 2, 2017 |
Foundation Medicine FOUNDATION MEDICINE, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 2, 2017 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commission |
|
| February 22, 2017 |
Exhibit 99.1 Foundation Medicine Announces 2016 Fourth Quarter and Year-End Results, Recent Highlights and 2017 Outlook CAMBRIDGE, Mass.-(BUSINESS WIRE)-February 22, 2017-Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the fourth quarter and year ended December 31, 2016. Highlights for the quarter and year included: Fourth quarter revenue of $28.8 million, 11% |
|
| February 22, 2017 |
Foundation Medicine FOUNDATION MEDICINE, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 22, 2017 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commis |
|
| February 14, 2017 |
FMI / Foundation Medicine, Inc. / GILDER GAGNON HOWE & CO LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 5)* Foundation Medicine, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 350456100 (CUSIP Number) December 31, 2016 (Da |
|
| January 30, 2017 |
TRANSACTIONS DURING PAST 60 DAYS EXHIBIT 1 TRANSACTIONS DURING PAST 60 DAYS The Reporting Persons engaged in the following transactions in shares of Common Stock of the Company during the past 60 days. |
|
| January 30, 2017 |
EXHIBIT 3 POWER OF ATTORNEY The undersigned, Daniel J. Donoghue, hereby appoints Mark Buckley his true and lawful attorney-in-fact and agent, with full power to execute and file with the United States Securities and Exchange Commission and any stock exchange or similar authority, for and on his behalf in any and all capacities, any and all reports required to be filed pursuant to Section 13 of the |
|
| January 30, 2017 |
EXHIBIT 2 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13D to which this Agreement is attached. Dated: January 30, 2017 DISCOVERY EQUITY PARTNERS, L.P. By Daniel J. Donoghue* Daniel J. Donoghue Manager DISCOVERY GROUP I, LLC By Daniel J. Donoghue* Daniel J. Donoghue Manager *By: /s/ Mark Buckley Mark Buckley Attorney-in-Fact for Daniel J. Donoghue |
|
| January 30, 2017 |
FMI / Foundation Medicine, Inc. / Discovery Group I, LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Foundation Medicine, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securi |
|
| January 9, 2017 |
Foundation Medicine FOUNDATION MEDICINE, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2017 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commissi |
|
| January 9, 2017 |
Exhibit 99.1 Foundation Medicine Reports Preliminary 2016 Results Achieves Total Revenue of Approximately $116.9 Million, a 25% Year Over Year Increase Reports 43,686 Clinical Tests in 2016, a 32% Year Over Year Increase CAMBRIDGE, Mass.-(BUSINESS WIRE)-January 9, 2017-Foundation Medicine (NASDAQ:FMI) today announced preliminary unaudited total revenue of approximately $28.8 million in the fourth |
|
| January 9, 2017 |
Exhibit 99.2 Partner for the Patient Journey J.P. Morgan Healthcare Conference CONFIDENTIAL 1 Investor Presentation CONFIDENTIAL Forward Looking Statement These slides and materials, including any accompanying oral presentation, contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as these statements are based upon our current exp |
|
| January 6, 2017 |
EX-10.1 2 d285878dex101.htm EX-10.1 Exhibit 10.1 150 Second Street, 1st Floor Cambridge Massachusetts 02141 TEL 617.418.2200 FAX 617.418.2201 January 5, 2017 Troy Cox 464 Tehama Street San Francisco, CA 94103 Re: Employment with Foundation Medicine, Inc. Dear Troy: On behalf of Foundation Medicine, Inc. (“Foundation Medicine” or “the Company”), I am very pleased to offer you the position of Chief |
|
| January 6, 2017 |
Foundation Medicine 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 5, 2017 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Comm |
|
| January 6, 2017 |
EX-10.4 5 d285878dex104.htm EX-10.4 Exhibit 10.4 WAIVER AND CONSENT January 5, 2017 WHEREAS, the Board of Directors (the “Board”) of Foundation Medicine, Inc. (the “Company”) desires to appoint Troy Cox as the Company’s Chief Executive Officer, to increase the size of the Board to ten (10) directors (the “Proposed Increase”) and to elect Mr. Cox as a director of the Company, in each case as of Feb |
|
| January 6, 2017 |
EX-10.3 Exhibit 10.3 January 5, 2017 Steven Kafka Re: Retention Bonus Dear Steve: As you know, Foundation Medicine, Inc. (?Foundation Medicine? or the ?Company?) has hired a new Chief Executive Officer who is expected to begin his employment at Foundation Medicine on February 6, 2017 (the ?New CEO Commencement Date?). At this time, the Company believes that your assistance during the one year peri |
|
| January 6, 2017 |
EX-10.2 3 d285878dex102.htm EX-10.2 Exhibit 10.2 January 5, 2017 Michael Pellini, M.D. 33841 Niguel Shores Drive Dana Point, CA 92629 Dear Dr. Pellini: This letter is intended to memorialize the understanding regarding the ending of your employment with Foundation Medicine, Inc. (“Foundation Medicine” or the “Company”) and your continuing role as an active member of the Company’s Board of Director |
|
| January 6, 2017 |
EX-99.1 6 d285878dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE Foundation Medicine Announces Executive Leadership Transition —Proven biopharma executive and commercial leader, Troy Cox, named as chief executive officer to succeed Michael Pellini, M.D.— —Dr. Pellini named chairman of the company’s Board of Directors— CAMBRIDGE, Mass. – January 6, 2017 - Foundation Medicine, Inc. (NASDAQ:FMI) today a |
|
| December 20, 2016 |
Foundation Medicine 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2016 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Co |
|
| November 16, 2016 |
fmi-ex1059.htm Exhibit 10.5 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 MASTER ivd collaboration AGREEMENT THIS MASTER IVD COLLABORATION AGREEMENT (this ?Agreement?) is made as of April 6, 2016 (the ?Signing Date?) by and between Foundation Medicine, Inc., a Delaware Corporatio |
|
| November 16, 2016 |
Foundation Medicine 10-Q/A (Quarterly Report) fmi-10qa20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi |
|
| November 2, 2016 |
Foundation Medicine FORM 10-Q (Quarterly Report) fmi-10q20160930.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file num |
|
| November 2, 2016 |
Foundation Medicine Announces 2016 Third Quarter Results and Recent Highlights Exhibit 99.1 Foundation Medicine Announces 2016 Third Quarter Results and Recent Highlights CAMBRIDGE, Mass.-(BUSINESS WIRE)-November 2, 2016-Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its third quarter ended September 30, 2016. Highlights for the quarter included: Achieved third quarter revenue of $29.4 million, 16% year-over-year growth; Reported 11 |
|
| November 2, 2016 |
Foundation Medicine FOUNDATION MEDICINE, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 2, 2016 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commiss |
|
| November 2, 2016 |
Exhibit 10.2 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 THIRD AMENDMENT TO COLLABORATION AGREEMENT This Third Amendment (“Third Amendment”) to the Collaboration Agreement (the “Agreement”) by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzac |
|
| October 28, 2016 |
Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty to its Board of Directors EX-99.1 Exhibit 99.1 NEWS RELEASE Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty to its Board of Directors CAMBRIDGE, Mass. ? October 27, 2016 - Foundation Medicine, Inc. (NASDAQ:FMI) today announced the election of Michael R. Dougherty to its board of directors. Mr. Dougherty brings more than 30 years of executive and operational leadership to his role as an independent direct |
|
| October 28, 2016 |
Foundation Medicine FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 26, 2016 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) |
|
| October 5, 2016 |
EX-10.1 Third Amendment to Lease ? Foundation Medicine, Inc. Exhibit 10.1 Page 1 THIRD AMENDMENT TO LEASE This Third Amendment to Lease (the ?Amendment?) is made as of September 30, 2016, by and between ARE-MA REGION NO. 50, LLC, a Delaware limited liability company, having an address at 385 East Colorado Boulevard, Suite 299, Pasadena, CA 91101 (?Landlord?), and FOUNDATION MEDICINE, INC., a Delaw |
|
| October 5, 2016 |
EX-10.3 Exhibit 10.3 ASSIGNMENT AND ASSUMPTION OF LEASE THIS ASSIGNMENT AND ASSUMPTION OF LEASE (the ?Assignment?) is entered into as of the 30th day of September, 2016, by and between BLUEBIRD BIO, INC., a Delaware corporation (?Assignor?), and FOUNDATION MEDICINE, INC., a Delaware corporation (?Assignee?). A. Assignor, as Tenant, and ARE-MA Region No. 50, LLC, a Delaware limited liability compan |
|
| October 5, 2016 |
EX-10.2 Exhibit 10.2 CONSENT TO ASSIGNMENT This Consent to Assignment (this ?Consent?) is made as of September 30, 2016, by ARE-MA REGION NO. 50, LLC, a Delaware limited liability company, having an address of 385 East Colorado Boulevard, Suite 299, Pasadena, California 91101 (?Landlord?), to BLUEBIRD BIO, INC., a Delaware corporation, having an address of 150 Second Street, First Floor, Cambridge |
|
| October 5, 2016 |
Foundation Medicine 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 30, 2016 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-36086 27-1316416 (State or other jurisdiction of incorporation) (C |
|
| August 3, 2016 |
Foundation Medicine FORM 10-Q (Quarterly Report) 10-Q 1 fmi-10q20160630.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| August 3, 2016 |
MASTER ivd collaboration AGREEMENT EX-10.5 5 fmi-ex105139.htm EX-10.5 IVD AGREEMENT Exhibit 10.5 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 MASTER ivd collaboration AGREEMENT THIS MASTER IVD COLLABORATION AGREEMENT (this “Agreement”) is made as of April 6, 2016 (the “Signing Date”) by and between Foundation Med |
|
| August 3, 2016 |
EX-10.2 2 fmi-ex102136.htm EX-10.2 A1 TO COLLABORATION Exhibit 10.2 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 FIRST AMENDMENT TO COLLABORATION AGREEMENT This First Amendment (“First Amendment”) to the Collaboration Agreement (the “Agreement”) by and between F. Hoffmann-La Roc |
|
| August 3, 2016 |
EX-10.3 3 fmi-ex103137.htm EX-10.3 A2 TO COLLABORATION Exhibit 10.3 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 SECOND AMENDMENT TO COLLABORATION AGREEMENT This Second Amendment (“Second Amendment”) to the Collaboration Agreement (the “Agreement”) by and between F. Hoffmann-La |
|
| August 3, 2016 |
Exhibit 10.4 FIRST AMENDMENT TO EX-US COMMERCIALIZATION AGREEMENT This First Amendment (“First Amendment”) to the Ex-US Commercialization Agreement (the “Agreement”), effective April 7, 2015, by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070, Basel, Switzerland ( “Roche”), on the one hand, and Foundation Medicine, Inc., with an office and |
|
| August 2, 2016 |
Foundation Medicine Announces 2016 Second Quarter Results and Recent Highlights EX-99.1 Exhibit 99.1 NEWS RELEASE Foundation Medicine Announces 2016 Second Quarter Results and Recent Highlights CAMBRIDGE, Mass. ? August 2, 2016?Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its second quarter ended June 30, 2016. Highlights for the quarter included: ? Achieved second quarter revenue of $28.2 million, 26% year-over-year growth; ? Repo |
|
| August 2, 2016 |
Foundation Medicine FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 2, 2016 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) ( |
|
| August 2, 2016 |
EX-10.1 Exhibit 10.1 Execution Version Confidential Credit Facility Agreement dated August 02, 2016 by and between Foundation Medicine, Inc. 150 Second St, Cambridge, MA 02141, United States of America (FMI or Borrower) and Roche Finance Ltd Grenzacherstrasse 122, 4058 Basel, Switzerland (Roche Finance or Lender) (the Borrower and the Lender, collectively the Parties) Table of Contents 1. Definiti |
|
| June 22, 2016 |
Foundation Medicine FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 16, 2016 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-36086 27-1316416 (State or other jurisdiction of incorporation) (C |
|
| June 8, 2016 |
CORRESP June 8, 2016 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attention: Craig Arakawa, Accounting Branch Chief, Office of Beverages, Apparel, and Mining Re: Foundation Medicine, Inc. Form 10-K for the fiscal year ended December 31, 2015 Filed March 1, 2016 File No. 001-36086 Dear Mr. Arakawa: We have received the com |
|
| May 3, 2016 |
Foundation Medicine 10-Q (Quarterly Report) 10-Q 1 fmi-10q20160331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| May 3, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2016 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commission F |
|
| May 3, 2016 |
Foundation Medicine Announces 2016 First Quarter Results and Recent Highlights Exhibit 99.1 Foundation Medicine Announces 2016 First Quarter Results and Recent Highlights CAMBRIDGE, Mass.-(BUSINESS WIRE)-May 3, 2016-Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its first quarter ended March 31, 2016. Highlights for the quarter included: Achieved first quarter revenue of $30.4 million, 57% year-over-year growth; Reported 8,985 clini |
|
| May 3, 2016 |
Exhibit 10.1 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 18th day of April, 2016, between ARE-7030 KIT CREEK, LLC, a Delaware limited liability company (“Landlord”), and FOUNDATION MEDICINE, INC., a Delaware corporation (“Tenant”). Building: 7010 Kit Creek Road, Research Triangle Park, North Carolina Premises: The Building, containing approximately 48,236 rentable square feet. |
|
| April 27, 2016 |
Foundation Medicine ADDITIONAL DEFINITIVE MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 27, 2016 |
DEF 14A 1 fmi-def14a061616.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 12, 2016 |
Foundation Medicine FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 6, 2016 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-36086 27-1316416 (State or other jurisdiction of incorporation) (C |
|
| March 28, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 28, 2016 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commi |
|
| March 1, 2016 |
Foundation Medicine FORM 10-K (Annual Report) Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 1, 2016 |
EX-21.1 EXHIBIT 21.1 SUBSIDIARIES OF REGISTRANT Foundation Medicine Securities Corporation, a Massachusetts corporation |
|
| February 23, 2016 |
Exhibit 99.1 Foundation Medicine Announces 2015 Fourth Quarter and Year-End Results, Recent Highlights and 2016 Outlook CAMBRIDGE, Mass.-(BUSINESS WIRE)-February 23, 2016-Foundation Medicine (NASDAQ: FMI) today reported financial and operational results for the fourth quarter and year ended December 31, 2015. Highlights for the quarter and year included: Fourth quarter revenue of $26.1 million, 39 |
|
| February 23, 2016 |
Foundation Medicine Form 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 23, 2016 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commis |
|
| February 16, 2016 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* Foundation Medicine, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 350465100 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of t |
|
| February 12, 2016 |
FMI / Foundation Medicine, Inc. / GILDER GAGNON HOWE & CO LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 4)* Foundation Medicine, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 350456100 (CUSIP Number) December 31, 2015 (Da |
|
| February 11, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Foundation Medicine, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 350465100 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| January 11, 2016 |
Foundation Medicine FOUNDATION MEDICINE, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 11, 2016 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commiss |
|
| January 11, 2016 |
2016 J.P. Morgan Annual Healthcare Conference Exhibit 99.2 2016 J.P. Morgan Annual Healthcare Conference These slides and the accompanying oral presentation contain forward-looking statements and information. These materials, including any accompanying oral presentation, contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as these statements are based upon our current expect |
|
| January 11, 2016 |
Exhibit 99.1 Foundation Medicine Reports Preliminary 2015 Results and Provides 2016 Business Outlook, including Commercial Launch of its ctDNA Assay Achieves Revenue of Approximately $93.2 Million, a 53% Year Over Year Increase Reports Approximately 33,000 Clinical Tests in 2015, a 36% Year Over Year Increase CAMBRIDGE, Mass.-(BUSINESS WIRE)-January 11, 2016-Foundation Medicine (NASDAQ:FMI) today |
|
| November 9, 2015 |
FMI / Foundation Medicine, Inc. / GILDER GAGNON HOWE & CO LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 3)* Foundation Medicine, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 350456100 (CUSIP Number) October 31, 2015 (Dat |
|
| November 3, 2015 |
Foundation Medicine FOUNDATION MEDICINE, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2015 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commiss |
|
| November 3, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 3, 2015 |
Exhibit 99.1 Foundation Medicine Announces 2015 Third Quarter Results and Recent Highlights Year-over-Year Third Quarter Revenues Grow 54%; FoundationCORE? Expands to Approximately 60,000 Patient Cases; ctDNA Product Launch on Track CAMBRIDGE, Mass.-(BUSINESS WIRE)-November 3, 2015-Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its third quarter ended Sep |
|
| August 24, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K/A 1 d895523d8ka.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2015 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (Stat |
|
| August 24, 2015 |
Exhibit 10.4 EXECUTION COPY ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 US Education Collaboration Agreement This Agreement is entered into with effect as of the Effective Date (as defined below) by and between Genentech, Inc. with an office and place of business at 1 DNA Way, |
|
| August 24, 2015 |
EX-10.2 Exhibit 10.2 EXECUTION COPY ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 Collaboration Agreement This Agreement is entered into with effect as of the Effective Date (as defined below) by and between F. Hoffmann-La Roche Ltd with an office and place of business at Grenzac |
|
| August 24, 2015 |
Foundation Medicine/Roche Binding Term Sheet for an In Vitro Diagnostics Collaboration EX-10.5 5 d895523dex105.htm EX-10.5 Exhibit 10.5 EXECUTION COPY ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 Foundation Medicine/Roche Binding Term Sheet for an In Vitro Diagnostics Collaboration This summary of terms (this “Binding Term Sheet”) between Foundation Medicine, Inc. |
|
| August 24, 2015 |
EX-10.3 3 d895523dex103.htm EX-10.3 Exhibit 10.3 EXECUTION COPY ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 Ex-US Commercialization Agreement This Agreement is entered into with effect as of the Effective Date (as defined below) by and between F. Hoffmann-La Roche Ltd with an o |
|
| August 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| July 29, 2015 |
Foundation Medicine FOUNDATION MEDICINE, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 29, 2015 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commission |
|
| July 29, 2015 |
Exhibit 99.1 Foundation Medicine Announces 2015 Second Quarter Results and Recent Highlights Year-over-Year Revenues Grow 55%; FoundationCORE? Expands to More Than 50,000 Patient Cases; Guidance Updated for 2015 CAMBRIDGE, Mass.-(BUSINESS WIRE)-July 29, 2015-Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its second quarter ended June 30, 2015. Highlights |
|
| June 23, 2015 |
Foundation Medicine FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 18, 2015 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-36086 27-1316416 (State or other jurisdiction of incorporation) (C |
|
| June 16, 2015 |
FMI / Foundation Medicine, Inc. / Google Ventures 2011, L.P. Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Foundation Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 350465100 (CUSIP Number) Jennifer L. Kercher, Esq. |
|
| June 10, 2015 |
Correspondence 150 Second Street, 1st Floor Cambridge Massachusetts 02141 TEL 617. |
|
| May 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Foundation Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 350465100 (CUSIP Number) Kevin Gillis Third Rock Ventures, LLC 29 Newbury Street, 3rd Floor, Boston, MA 02116 (617) 585-2000 (Name, Addres |
|
| May 11, 2015 |
Foundation Medicine FOUNDATION MEDICINE, INC. 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2015 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commission |
|
| May 11, 2015 |
Foundation Medicine Announces 2015 First Quarter Results and Recent Highlights Exhibit 99.1 Foundation Medicine Announces 2015 First Quarter Results and Recent Highlights CAMBRIDGE, Mass.-(BUSINESS WIRE)-May 11, 2015-Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its first quarter ended March 31, 2015. Highlights for the quarter included: 7,854 clinical tests reported in the first quarter, 67% year-over-year growth First quarter rev |
|
| May 11, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 30, 2015 |
Foundation Medicine ADDITIONAL DEFINITIVE MATERIALS DEFA14A 1 brp65761-defa14061815.htm ADDITIONAL DEFINITIVE MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 30, 2015 |
Foundation Medicine DEFINITIVE PROXY STATEMENT DEF 14A 1 brp65951-def14a061815.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential |
|
| April 23, 2015 |
Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to (i) the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, $0.0001 par value per share, of Foundation Medicine, Inc. and (ii) that this Joi |
|
| April 23, 2015 |
FMI / Foundation Medicine, Inc. / ROCHE HOLDING LTD - SC 13D/A Activist Investment SC 13D/A 1 dp55370sc13da-2.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2) Under the Securities Exchange Act of 1934 Foundation Medicine, Inc. (Name of Issuer) Common Stock, 0.0001 par value per share (Title of Class of Securities) 350456100 (CUSIP Number) Beat Kraehenmann Roche Holding Ltd Grenzacherstrasse 124 CH-4070 Basel, S |
|
| April 22, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Foundation Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 350465100 (CUSIP Number) Kevin Gillis Third Rock Ventures, LLC 29 Newbury Street, 3rd Floor, Boston, MA 02116 (617) 585-2000 (Name, Address |
|
| April 17, 2015 |
FMI / Foundation Medicine, Inc. / Google Ventures 2011, L.P. - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Foundation Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 350465100 (CUSIP Number) Jennifer L. Kercher, Esq. 1 |
|
| April 14, 2015 |
Roche announces final results of tender offer for Foundation Medicine, Inc. Exhibit (a)(5)(viii) Media Release Basel, 14 April 2015 Roche announces final results of tender offer for Foundation Medicine, Inc. |
|
| April 14, 2015 |
Foundation Medicine FORM 8-K AMENDMENT (Current Report/Significant Event) Form 8-K Amendment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 7 to SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 FOUNDATION MEDICINE, INC. (Name of Subject Company) ROCHE HOLDINGS, INC. (Names of Filing Persons – Offeror) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 350465100 (Cusip N |
|
| April 14, 2015 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 7) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Foundation Medicine, Inc. (Name of Subject Company) Foundation Medicine, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities |
|
| April 9, 2015 |
Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to (i) the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, $0.0001 par value per share, of Foundation Medicine, Inc. and (ii) that this Joi |
|
| April 9, 2015 |
FMI / Foundation Medicine, Inc. / ROCHE HOLDING LTD - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 1) Under the Securities Exchange Act of 1934 Foundation Medicine, Inc. (Name of Issuer) Common Stock, 0.0001 par value per share (Title of Class of Securities) 350456100 (CUSIP Number) Beat Kraehenmann Roche Holding Ltd Grenzacherstrasse 124 CH-4070 Basel, Switzerland Telephone: +41-61-688-1111 (N |
|
| April 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 6 to SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 FOUNDATION MEDICINE, INC. (Name of Subject Company) ROCHE HOLDINGS, INC. (Names of Filing Persons – Offeror) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 350465100 (Cusip N |
|
| April 7, 2015 |
EX-3.1 Exhibit 3.1 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FOUNDATION MEDICINE, INC. Foundation Medicine, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Foundation Medicine, Inc. The date of the filing of its original Certificate of Incorporation with the Sec |
|
| April 7, 2015 |
EX-16.1 Exhibit 16.1 April 7, 2015 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated April 7, 2015, of Foundation Medicine, Inc. and are in agreement with the statements contained in paragraphs one, two, and three of Item 4.01(a) therein. We have no basis to agree or disagree with other statements of the regist |
|
| April 7, 2015 |
Roche announces preliminary results of tender offer for Foundation Medicine, Inc. Media Release Basel, 7 April 2015 Roche announces preliminary results of tender offer for Foundation Medicine, Inc. |
|
| April 7, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 6, 2015 FOUNDATION MEDICINE, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commis |
|
| April 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 6) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Foundation Medicine, Inc. (Name of Subject Company) Foundation Medicine, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 35046510 |
|
| April 7, 2015 |
EX-99.1 Exhibit 99.1 NEWS RELEASE Foundation Medicine and Roche Complete Strategic Transaction to Advance Molecular Information and Precision Medicine in Oncology ?Transaction Closing Results in $250M in Gross Proceeds for Foundation Medicine and Commences R&D and Commercial Agreements with Roche? ?Roche Gains Minority Board Representation and Becomes Majority Shareholder in Foundation Medicine? C |
|
| April 3, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 5 to SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 FOUNDATION MEDICINE, INC. (Name of Subject Company) ROCHE HOLDINGS, INC. (Names of Filing Persons – Offeror) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 350465100 (Cusip N |
|
| April 2, 2015 |
Foundation Medicine FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 2, 2015 FOUNDATION MEDICINE, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-36086 27-1316416 (State or other jurisdiction of incorporation) (C |
|
| April 2, 2015 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 5) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Foundation Medicine, Inc. (Name of Subject Company) Foundation Medicine, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities |
|
| April 2, 2015 |
EX-99.1 Exhibit 99.1 NEWS RELEASE Foundation Medicine Stockholders Approve Pending Roche Transaction at Special Meeting of Stockholders ? Pending Roche Tender Offer Scheduled to Expire at the End of the Day on Monday, April 6, 2015 ? CAMBRIDGE, Mass. ?April 2, 2015 ? Foundation Medicine, Inc. (NASDAQ:FMI) today announced that its stockholders approved each proposal presented at the special meeting |
|
| March 24, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 FOUNDATION MEDICINE, INC. (Name of Subject Company) ROCHE HOLDINGS, INC. (Names of Filing Persons – Offeror) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 350465100 (Cusip N |
|
| March 23, 2015 |
Foundation Medicine FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 23, 2015 FOUNDATION MEDICINE, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-36086 27-1316416 (State or other jurisdiction of incorporation) ( |
|
| March 23, 2015 |
Foundation Medicine SCHEDULE 14D-9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 4) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Foundation Medicine, Inc. (Name of Subject Company) Foundation Medicine, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 35046510 |
|
| March 23, 2015 |
EX-99.1 Exhibit 99.1 NEWS RELEASE Foundation Medicine Announces Proposed Changes to its Board of Directors in Connection with the Pending Roche Transaction CAMBRIDGE, Mass. ? March 23, 2015 ? Foundation Medicine, Inc. (NASDAQ:FMI) today announced proposed changes to its Board of Directors in connection with its pending strategic collaboration with Roche. Under the terms of the agreement with Roche |
|
| March 23, 2015 |
EX-99.2 Exhibit 99.2 NEWS RELEASE Foundation Medicine Announces Executive Promotions and Expanded Leadership Team to Complement Global Growth Initiatives CAMBRIDGE, Mass. ? March 23, 2015 ? Foundation Medicine, Inc. (NASDAQ:FMI) today announced four executive promotions and a new leadership appointment to support and accelerate the company?s United States and global commercial and operational grow |
|
| March 23, 2015 |
DEFA14A 1 d897238ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as |
|
| March 19, 2015 |
DEFA14A 1 d893781ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as |
|
| March 13, 2015 |
EX-21.1 EXHIBIT 21.1 SUBSIDIARIES OF REGISTRANT Foundation Medicine Securities Corporation, a Massachusetts corporation |
|
| March 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-3 |
|
| March 12, 2015 |
Foundation Medicine 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2015 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Commi |
|
| March 12, 2015 |
EX-10.1 Exhibit 10.1 EXHIBIT 1, LEASE DATA Ten Canal Park Cambridge, Massachusetts 02141 (the ?Building?) Execution Date: March 11, 2015 Tenant: Foundation Medicine, Inc., a Delaware corporation Tenant?s Address: 150 Second Street, First Floor Cambridge, Massachusetts 02141 Landlord: BCSP Cambridge Ten Property LLC, a Delaware limited liability company Landlord?s Address: c/o Beacon Capital Partne |
|
| March 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 5, 2015 |
Foundation Medicine DEFINITIVE ADDITIONAL MATERIALS DEFA14A 1 d884896ddefa14a.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of |
|
| March 2, 2015 |
ROCHE EXTENDS TENDER OFFER FOR FMI Exhibit 99.1 Media Release Basel, 2 March 2015 ROCHE EXTENDS TENDER OFFER FOR FMI Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has extended the expiration of its tender offer to purchase up to 15,604,288 of the outstanding common shares of Foundation Medicine, Inc. (NASDAQ: FMI), at a price of $50.00 per share in cash, to 12:00 midnight, New York City time, at the end of the day on M |
|
| March 2, 2015 |
FMI / Foundation Medicine, Inc. SC TO-T/A - - FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 FOUNDATION MEDICINE, INC. (Name of Subject Company) ROCHE HOLDINGS, INC. (Names of Filing Persons – Offeror) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 350465100 (Cusip N |
|
| March 2, 2015 |
FMI / Foundation Medicine, Inc. SC 14D9/A - - SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Foundation Medicine, Inc. (Name of Subject Company) Foundation Medicine, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities |
|
| February 26, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 24, 2015 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation |
|
| February 26, 2015 |
FMI / Foundation Medicine, Inc. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| February 26, 2015 |
EX-99.1 Exhibit 99.1 1 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us © 2015 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. ‘Thomson Reuters’ and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its |
|
| February 26, 2015 |
FMI / Foundation Medicine, Inc. SC 14D9/A - - SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Foundation Medicine, Inc. (Name of Subject Company) Foundation Medicine, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities |
|
| February 26, 2015 |
EX-(a)(15) EX - (a)(15) 1 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us © 2015 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. ‘Thomson Reuters’ and the Thomson Reuters logo are registered trademarks of Thomson Reuters and i |
|
| February 24, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 24, 2015 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other jurisdiction of incorporation) (Co |
|
| February 24, 2015 |
EX-99.1 2 d880440dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE Foundation Medicine Announces 2014 Fourth Quarter and Year-End Results, Recent Highlights and 2015 Outlook CAMBRIDGE, Mass. – February 24, 2015 - Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for the fourth quarter and year ended December 31, 2014. Highlights for the quarter and year include: • 7, |
|
| February 20, 2015 |
FMI / Foundation Medicine, Inc. SC TO-T/A - - FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 FOUNDATION MEDICINE, INC. (Name of Subject Company) ROCHE HOLDINGS, INC. (Names of Filing Persons – Offeror) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 350465100 (Cusip N |
|
| February 20, 2015 |
FMI / Foundation Medicine, Inc. SC 14D9/A - - SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Foundation Medicine, Inc. (Name of Subject Company) Foundation Medicine, Inc. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 35046510 |
|
| February 19, 2015 |
FMI / Foundation Medicine, Inc. DEF 14A - - DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 17, 2015 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Foundation Medicine, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 350465100 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of t |
|
| February 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Foundation Medicine, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 350465100 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Foundation Medicine, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 350465100 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 10, 2015 |
FMI / Foundation Medicine, Inc. / GILDER GAGNON HOWE & CO LLC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 2)* Foundation Medicine, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 350456100 (CUSIP Number) December 31, 2014 (Da |
|
| February 3, 2015 |
FMI / Foundation Medicine, Inc. SC TO-T/A - - FORM SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 FOUNDATION MEDICINE, INC. (Name of Subject Company) ROCHE HOLDINGS, INC. (Names of Filing Persons – Offeror) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 350465100 (Cusip N |
|
| February 3, 2015 |
Media Release Basel, 2 February 2015 Roche commences tender offer for up to 15,604,288 shares of Foundation Medicine, Inc. |
|
| February 2, 2015 |
EX-(a)(1)(iii) Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of Foundation Medicine, Inc. |
|
| February 2, 2015 |
FMI / Foundation Medicine, Inc. DEFA14A - - FORM 8-K/A FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2015 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other Jurisdiction of Incorporat |
|
| February 2, 2015 |
Ex-US Commercialization Agreement EX-10.3 Exhibit 10.3 EXECUTION COPY ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 Ex-US Commercialization Agreement This Agreement is entered into with effect as of the Effective Date (as defined below) by and between F. Hoffmann-La Roche Ltd with an office and place of business |
|
| February 2, 2015 |
FMI / Foundation Medicine, Inc. PRE 14A - - PRE 14A PRE 14A 1 d858509dpre14a.htm PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commissi |
|
| February 2, 2015 |
EX-(a)(1)(I) Table of Contents Exhibit (a)(1)(i) Offer to Purchase for Cash up to 15,604,288 Outstanding Shares of Common Stock of Foundation Medicine, Inc. |
|
| February 2, 2015 |
US Education Collaboration Agreement EX-10.4 Exhibit 10.4 EXECUTION COPY ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 US Education Collaboration Agreement This Agreement is entered into with effect as of the Effective Date (as defined below) by and between Genentech, Inc. with an office and place of business at 1 D |
|
| February 2, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2015 Foundation Medicine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36086 27-1316416 (State or other Jurisdiction of Incorporat |
